A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
A phase 1/2 trial of Rilvegostomig, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06996782 by AstraZeneca, with 152 participants planned, started 2025-11-24 and due to reach its primary completion in 2029-02-23. Interventions recorded: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Ramucirumab, Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
Shares Rilvegostomig, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Rilvegostomig, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, AstraZeneca.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, Ramucirumab, AstraZeneca, Small-cell lung cancer.